C85.88

Clinical Causes: Genetic mutations leading to abnormal lymphocyte growth Age-related changes, with higher incidence in older adults Certain infections, such as HIV, Epstein-Barr virus (EBV), and Helicobacter pylori Immunosuppressive therapies or conditions, which weaken immune defenses Environmental exposures, like pesticides and certain chemicals

Key Symptoms: Swollen, painless lymph nodes in multiple areas of the body Unexplained weight loss Persistent fever, often without obvious infection Night sweats that soak clothing or bedding Fatigue and general weakness Potential pain or pressure sensations if lymph nodes press on nearby structures Frequent infections due to immune system interference

Diagnosis Path: Diagnosing non-Hodgkin lymphoma affecting multiple sites involves a combination of clinical evaluations and specialized testing. Common diagnostic steps include: - Physical examination to identify enlarged lymph nodes - Blood tests to assess overall health, blood cell counts, and possible markers - Imaging studies such as CT scans, PET scans, or MRI to locate and evaluate the extent of lymph node involvement - Biopsy procedures to extract tissue from affected lymph nodes for microscopic diagnosis - Additional tests like bone marrow biopsies if systemic involvement is suspected Such a thorough approach helps determine the precise type and spread of the lymphoma, guiding treatment decisions.

Treatment Protocols: Treatment options for multiple-site non-Hodgkin lymphoma aim to control disease progression and improve quality of life. They typically include: - Chemotherapy regimens designed to target rapidly dividing cancer cells - Targeted therapies that interfere with specific molecules involved in cancer growth - Immunotherapy, which harnesses the patient’s immune system to attack lymphoma cells - Radiation therapy in certain cases to reduce localized lymph node involvement - Stem cell or bone marrow transplants, particularly in relapsed or aggressive cases The choice of treatment depends on factors such as the specific lymphoma subtype, stage, patient’s overall health, and response to initial therapies.